Loading...
NPI 1396810834 · Las Vegas, NV · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Wolfram Samlowski is a hematology & oncology physician provider located in Las Vegas, Nevada. This profile covers 68 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Wolfram Samlowski |
| Address | 2050 Pinto Ln Ste 200 |
| City | Las Vegas |
| State | NV |
| ZIP | 89106 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | November 21, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.4M |
| Medicaid | $8.1K |
Specialty and service mix align with infusion-based oncology care: the top Medicare revenue codes are oncology biologic/drug administration codes (J9298, J9271, J9299) and chemotherapy administration CPT 96413, indicating the practice primarily delivers high-cost immunotherapy and infusion oncology services rather than office-based primary care. The code set (including supportive drugs like J1568, J0897 and procedure codes 96365 and 96413) is consistent with an outpatient hematology–oncology infusion clinic model focused on systemic cancer therapies and associated monitoring labs.
High revenue concentration in a few drugs on Medicare: precomputed figures show the top 3 Medicare codes by revenue account for 84.8% of this provider’s total Medicare revenue, with J9298 alone contributing $954.5K (39.7% of Medicare revenue). This concentration indicates Medicare income is heavily dependent on a small number of high-cost injectable oncology agents.
Medicare scale far exceeds Medicaid for this provider: lifetime Medicare revenue is $2.4M versus lifetime Medicaid revenue of $8.1K, so this entity functions effectively as a Medicare-centric provider with negligible Medicaid billing in scale. The Medicaid activity is minimal relative to Medicare and does not materially diversify payer exposure.
Medicaid billing is narrowly focused and limited in-state: all reported Medicaid revenue (100.0%) comes from a single code, 99214, totaling $8.1K and ranking in the 28th percentile among in-state peers. This suggests the provider’s Medicaid interactions are limited to moderate-complexity outpatient E/M visits rather than infusion drug billing under Medicaid.
Competitive standing on leading Medicare drug codes is modest to typical nationally: for J9298 the provider ranks #3 of 5 (50th percentile) indicating typical volume among the very small national peer set for that specific combination drug product; J9271 ranks #718 of 1841 (61st percentile) and J9299 ranks #152 of 505 (70th percentile), all described as "typical, unremarkable volume" or near-typical. These ranks indicate the provider is a steady, not dominant, participant in national utilization of these oncology injectables.
One notable above-typical office visit volume on Medicare: 99213 appears with 807 claims and is marked as "notably above typical national volume" (98th percentile), suggesting relatively high use of lower-complexity established patient E/M visits alongside the infusion practice. This may reflect frequent follow-up visits tied to ongoing oncology treatment.
Practice tenure and stability: the NPI was enumerated on 2006-11-21 (about 20 years ago), indicating long-standing enrollment and likely sustained operation in the market; the extended tenure supports interpreting billing patterns as established practice behavior rather than a transient billing spike.
Procedural and lab ancillary services support infusion care: consistent medium-to-high percentiles for lab CPTs (80053, 85025, 84443, 84439, 83615 all with high percentile ranks) and imaging/infusion codes (96413, 96365) indicate the provider bills routine monitoring labs and procedural services commonly paired with oncology infusions, reinforcing the clinical focus on systemic therapy and associated monitoring.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
68 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9298 | Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg | 6,720 | $140 | $954.5K |
| J9271 | Injection, pembrolizumab, 1 mg | 14,600 | $40 | $627.8K |
| J9299 | Injection, nivolumab, 1 mg | 20,760 | $20 | $456.7K |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 1,760 | $30 | $59.8K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 590 | $100 | $57.9K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 810 | $70 | $53.3K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 350 | $110 | $37K |
| J0897 | Injection, denosumab, 1 mg | 1,680 | $20 | $31.9K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 9,200 | $1 | $18.4K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 1,100 | $10 | $11K |
Showing 1–10 of 68
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 68 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
68 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9298 | 1 | 10 | 6,720 | $140 | $957.6K |
| J9271 | 14 | 40 | 13,000 | $40 | $625.8K |
| J9299 | 2 | 10 | 14,400 | $20 | $362K |
| J1568 | 13 | 10 | 4,470 | $30 | $164.2K |
| J0897 | 54 | 70 | 3,630 | $20 | $94.6K |
| J0881 | 22 | 30 | 17,400 | $1 | $49.5K |
| 99233 | 934 | 1,150 | 150 | $90 | $26.8K |
| J9217 | 30 | 40 | 120 | $130 | $23.9K |
| 96413 | 17 | 70 | 210 | $100 | $23.7K |
| 99232 | 1,041 | 1,340 | 140 | $60 | $23.7K |
Showing 1–10 of 68
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 90 | $90 | $8.1K |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,623 | 2,250 | 290 | $60 | $138K |
Other providers in the same ZIP code as Wolfram Samlowski, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.